Navigation Links
Van Andel Institute Joins the MetaMiner Oncology Partnership Program
Date:3/31/2009

ST. JOSEPH, Mich., March 31 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Craig Webb, Ph.D., director of the Program of Translational Medicine at Grand Rapids, Mich.-based Van Andel Institute, has joined the MetaMiner Oncology Partnership Program.

The goal of the program is to develop a proprietary oncology pathway analysis platform built by experts in the field. This includes developing a series of blueprint pathway maps for cancers, collecting public domain experimental data and normalizing, parsing and making it available for use, as well as developing cancer specific ontologies.

"We feel that it is important to support such an initiative. There is an increasing amount of information in the cancer literature but no one has brought it all together in a set of comprehensive pathway maps that can be further explored," said Webb "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."

Van Andel Institute announced in February an alliance and affiliation agreement with the Phoenix-based Translational Genomics Research Institute (TGen), one of the preeminent translational research organizations in the biomedical industry.

"Craig does amazing work at VAI, working with late-stage cancer patients to give them hope, and we are pleased to have him on our team," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience in cancer and have received millions of dollars in grants to fund our pioneering research."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

About Van Andel Institute

Established by Jay and Betty Van Andel in 1996, Van Andel Institute (VAI) is an independent research and educational organization based in Grand Rapids, Mich., dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. Van Andel Research Institute (VARI), the research arm of VAI, is dedicated to probing the genetic, cellular and molecular origins of cancer, Parkinson and other diseases and working to translate those findings into effective therapies. This is accomplished through the work of over 200 researchers in 18 on-site laboratories, in laboratories in Singapore and Nanjing, and in collaborative partnerships that span the globe. For additional information, visit: www.vai.org.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
2. Repair Stem Cell Institute Warns About Real Cost of Embryonic Stem Cell Research
3. Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition
4. Repair Stem Cell Institute Weighs in on Reversal of Embryonic Stem Cell Policy
5. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
6. WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institutes Quantitative PCR Conference
7. EPA Awards Lovelace Respiratory Research Institute $500,000 for Air Quality Research
8. Oregon Health & Science University Knight Cancer Institute Enhances Patient Care With Monaco(R) Radiation Treatment Planning System
9. DuPont and International Rice Research Institute Partner to Boost Rice Yields
10. Prous Institute Presents Innovative Approach to Drug Discovery
11. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2020)... ... August 29, 2020 , ... ... Nutrition manufacturing capability in Wuxi, China. The new plant operation will provide the ... and advanced technology. , “This facility will improve the flexibility of our ...
(Date:8/15/2020)... SCOTTSDALE, Ariz. (PRWEB) , ... August 13, 2020 ... ... 4254 on its annual Inc. 5000 list, the most prestigious ranking of the ... successful companies within the American economy’s most dynamic segment—its independent small businesses. Intuit, ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... validation engineering firm, is making available for free its new white paper ... concurrent transport simulation testing into today’s biologics licensing application (BLA). In response, ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
Breaking Biology Technology:
(Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... Commercial ... hangs on pharma’s ability to discover a COVID cure or vaccine, the global economic ... competitive and price pressure is not going away and capturing full value from every ...
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
(Date:6/28/2020)... Switzerland (PRWEB) , ... June ... ... provider of enterprise software solutions for biopharmaceutical R&D, today announced that it ... company developing innovative, full-length multispecific antibodies (Multiclonics®), to support their translational and ...
Breaking Biology News(10 mins):